Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used

Willem Lesterhuis; G. Schreibelt; N.M. Scharenborg; H.M.-I.H. Brouwer; M.-J.P. Gerritsen; S. Croockewit; P.G. Coulie; R. Torensma; G.J. Adema; C.G. Figdor; I.J.M. De Vries; C.J.A. Punt

doi:10.1007/s00262-010-0942-x

Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used

Willem Lesterhuis, G. Schreibelt, N.M. Scharenborg, H.M.-I.H. Brouwer, M.-J.P. Gerritsen, S. Croockewit, P.G. Coulie, R. Torensma, G.J. Adema, C.G. Figdor, I.J.M. De Vries, C.J.A. Punt

Research output: Contribution to journal › Article › peer-review

62 Citations (Scopus)

Original language	English
Pages (from-to)	249-260
Journal	Cancer Immunology Immunotherapy
Volume	60
Issue number	2
DOIs	https://doi.org/10.1007/s00262-010-0942-x
Publication status	Published - 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00262-010-0942-x

Cite this

Lesterhuis, W., Schreibelt, G., Scharenborg, N. M., Brouwer, HM.-IH., Gerritsen, M.-JP., Croockewit, S., Coulie, P. G., Torensma, R., Adema, G. J., Figdor, C. G., De Vries, I. J. M., & Punt, C. J. A. (2011). Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. Cancer Immunology Immunotherapy, 60(2), 249-260. https://doi.org/10.1007/s00262-010-0942-x

@article{3028198585df4cd3b6261d6d1ed8dd85,

title = "Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used",

author = "Willem Lesterhuis and G. Schreibelt and N.M. Scharenborg and H.M.-I.H. Brouwer and M.-J.P. Gerritsen and S. Croockewit and P.G. Coulie and R. Torensma and G.J. Adema and C.G. Figdor and {De Vries}, I.J.M. and C.J.A. Punt",

year = "2011",

doi = "10.1007/s00262-010-0942-x",

language = "English",

volume = "60",

pages = "249--260",

journal = "Cancer Immunology Immunotherapy",

issn = "0340-7004",

publisher = "Springer",

number = "2",

}

Lesterhuis, W, Schreibelt, G, Scharenborg, NM, Brouwer, HM-IH, Gerritsen, M-JP, Croockewit, S, Coulie, PG, Torensma, R, Adema, GJ, Figdor, CG, De Vries, IJM & Punt, CJA 2011, 'Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used', Cancer Immunology Immunotherapy, vol. 60, no. 2, pp. 249-260. https://doi.org/10.1007/s00262-010-0942-x

Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. / Lesterhuis, Willem; Schreibelt, G.; Scharenborg, N.M. et al.
In: Cancer Immunology Immunotherapy, Vol. 60, No. 2, 2011, p. 249-260.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used

AU - Lesterhuis, Willem

AU - Schreibelt, G.

AU - Scharenborg, N.M.

AU - Brouwer, H.M.-I.H.

AU - Gerritsen, M.-J.P.

AU - Croockewit, S.

AU - Coulie, P.G.

AU - Torensma, R.

AU - Adema, G.J.

AU - Figdor, C.G.

AU - De Vries, I.J.M.

AU - Punt, C.J.A.

PY - 2011

Y1 - 2011

U2 - 10.1007/s00262-010-0942-x

DO - 10.1007/s00262-010-0942-x

M3 - Article

SN - 0340-7004

VL - 60

SP - 249

EP - 260

JO - Cancer Immunology Immunotherapy

JF - Cancer Immunology Immunotherapy

IS - 2

ER -